<DOC>
	<DOCNO>NCT01207830</DOCNO>
	<brief_summary>The purpose study provide initial clinical data support feasibility use ValenTx Endo Bypass system enhance weight loss co-morbidity resolution morbidly obese subject</brief_summary>
	<brief_title>Feasibility Trial ValenTx Endo Bypass System ValenTx Endo Bypass System Obese Subjects</brief_title>
	<detailed_description>This single center , open label , feasibility study whose major aim determine feasibility ( base safety , efficacy device performance ) ValenTx Endo Bypass system replaceable sleeve . Also , use tag replacement device may develop implement individual attachment tag need replace follow initial implant .</detailed_description>
	<criteria>Male female 18 55 year age Subject BMI &gt; 35 kg/m2 &lt; = 50 kg/m2 , without comorbid condition ( ) Documented failure nonsurgical weight loss method Willing comply study procedure visit schedule Willing able provide inform consent Pregnancy intention become pregnant within study duration ( Women childbearing potential participating study must negative serum pregnancy test result screen use medically acceptable form contraception . Medically acceptable form contraception include oral contraceptive , injectable implantable method , intrauterine device , properly use doublebarrier contraception , eg condom plus diaphragm . If screening pregnancy test do great 7 day implant , woman childbearing potential must another serum pregnancy test result implantation . Any woman become pregnant treatment period must withdraw study ) Endoscopic lesion important hiatal hernia , gastric duodenal ulcer , atresias stenosis , polyps stomach Subject potential upper gastrointestinal bleeding esophageal gastric varix , MalloryWeis syndrome congenital acquire intestinal telangiectasia Past history esophageal gastric/GI surgery , obstruction , adhesive peritonitis , large hiatal hernia ( &gt; 3 cm ) IBS , unexplained intermittent vomiting , severe abdominal pain chronic constipation within 60 day study day 0 Unexplained anaemia , Pancreatitis , Portal hypertension , Esophagitis Barrett 's esophagus , know gallstone anomaly GI tract Any bodily infection within 30 day study day 0 ( implant day ) Prolonged steroid use Hep C HIV positive Known allergy device material Use weight loss medication within 2 month prior enrollment throughout study period Recent ongoing cancer , history severe renal , hepatic , cardiovascular pulmonary disease transplant Inability tolerate antiinflammatory medication Evidence psychiatric problem dietary habit would contraindicate study treatment Active drug alcohol addiction within 12 month enrollment throughout study duration Prior history inflammatory diseases GI tract , ( e.g. , esophagitis , varix , gastric duodenal ulceration , Crohn 's disease ; congenital acquire GI anomaly , e.g. , bowel stricture ) Ongoing treatment anticoagulant , steroid , aspirin , NSAIDs , gastric irritant within 1 month prior enrollment throughout study period Participation previous ( within 60 day study day 0 ) ongoing clinical trial current past usage ( within 60 day study day 0 ) investigation drug device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Obesity</keyword>
</DOC>